Author
Listed:
- Kyren A. Lazarus
(University of Cambridge
Cambridge Cancer Centre)
- Fazal Hadi
(University of Cambridge
Cambridge Cancer Centre)
- Elisabetta Zambon
(University of Cambridge
Cambridge Cancer Centre)
- Karsten Bach
(University of Cambridge
Cambridge Cancer Centre)
- Maria-Francesca Santolla
(University of Cambridge
University of Calabria)
- Julie K. Watson
(University of Cambridge)
- Lucia L. Correia
(University of Cambridge)
- Madhumita Das
(Lancaster Road)
- Rosemary Ugur
(University of Cambridge
Cambridge Cancer Centre)
- Sara Pensa
(University of Cambridge
Cambridge Cancer Centre)
- Lukas Becker
(University of Cambridge)
- Lia S. Campos
(Wellcome Trust Sanger Institute)
- Graham Ladds
(University of Cambridge)
- Pentao Liu
(Wellcome Trust Sanger Institute)
- Gerard I. Evan
(University of Cambridge)
- Frank M. McCaughan
(University of Cambridge)
- John Quesne
(Lancaster Road
University of Leicester
University Hospitals Leicester NHS trust)
- Joo-Hyeon Lee
(University of Cambridge)
- Dinis Calado
(The Francis Crick Institute)
- Walid T. Khaled
(University of Cambridge
Cambridge Cancer Centre
University of Cambridge)
Abstract
Patients diagnosed with lung squamous cell carcinoma (LUSC) have limited targeted therapies. We report here the identification and characterisation of BCL11A, as a LUSC oncogene. Analysis of cancer genomics datasets revealed BCL11A to be upregulated in LUSC but not in lung adenocarcinoma (LUAD). Experimentally we demonstrate that non-physiological levels of BCL11A in vitro and in vivo promote squamous-like phenotypes, while its knockdown abolishes xenograft tumour formation. At the molecular level we found that BCL11A is transcriptionally regulated by SOX2 and is required for its oncogenic functions. Furthermore, we show that BCL11A and SOX2 regulate the expression of several transcription factors, including SETD8. We demonstrate that shRNA-mediated or pharmacological inhibition of SETD8 selectively inhibits LUSC growth. Collectively, our study indicates that BCL11A is integral to LUSC pathology and highlights the disruption of the BCL11A–SOX2 transcriptional programme as a novel candidate for drug development.
Suggested Citation
Kyren A. Lazarus & Fazal Hadi & Elisabetta Zambon & Karsten Bach & Maria-Francesca Santolla & Julie K. Watson & Lucia L. Correia & Madhumita Das & Rosemary Ugur & Sara Pensa & Lukas Becker & Lia S. Ca, 2018.
"BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma,"
Nature Communications, Nature, vol. 9(1), pages 1-11, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05790-5
DOI: 10.1038/s41467-018-05790-5
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05790-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.